Drug Trial Radar · NCT01627613
Study in Intensive Care Patients to Investigate the Clinical Effect of Repetitive Orally Inhaled Doses of AP301 on Alveolar Liquid Clearance in Acute Lung Injury
Last checked: Nov 19, 2026Latest source record: Nov 18, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Jul 2012
Primary completion
May 2014
Study completion Aug 2014
Sponsor
- Lead sponsor
- Apeptico Forschung und Entwicklung GmbHIndustry
- Sponsor type
- Industry
- First posted
- Jun 26, 2012
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the effect of orally inhaled AP301 on alveolar liquid clearance in ALI (acute lung injury) patients with the purpose to assess the treatment associated changes of extravascular lung water (EVLW) within 7 days of treatment.
Conditions
- Acute Lung Injury
Interventions
AP301Drug
AP301 25 mg powder for reconstitution for solution for inhalation Orally delivered doses of 87.6 mg AP301 are inhaled every 12 hours (± 30 min), for a total of 7 days.
Saline solutionDrug
Placebo solution (0.9% physiologic NaCl) is inhaled every 12 hours (± 30 min), for a total of 7 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- change in extravascular lung water within 7 days of treatmentTime frame: change from baseline - day 7
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Department of Anesthesia, General Intensive Care and Pain Control,Medical University of Vienna
Vienna, Austria
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.